How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/belladonna-and-opium-suppositories.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Belladonna and Opium Suppositories — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Belladonna and Opium Suppositories (Belladonna and Opium Suppositories) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic/opioid combination. Area: Gastroenterology.

marketed Anticholinergic/opioid combination Muscarinic acetylcholine receptors; mu opioid receptors Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Belladonna and Opium Suppositories (Belladonna and Opium Suppositories) — Kristina A. Butler. Belladonna alkaloids block muscarinic cholinergic receptors to reduce smooth muscle spasms, while opium alkaloids activate opioid receptors to provide analgesia and further reduce intestinal motility.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Belladonna and Opium Suppositories TARGET	Belladonna and Opium Suppositories	Kristina A. Butler	marketed	Anticholinergic/opioid combination	Muscarinic acetylcholine receptors; mu opioid receptors
Atropine/Remifentanil	Atropine/Remifentanil	King Saud University	marketed	Anticholinergic/Opioid combination	Muscarinic acetylcholine receptor (atropine); mu-opioid receptor (remifentanil)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic/opioid combination class)

Kristina A. Butler · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Belladonna and Opium Suppositories — Competitive Intelligence Brief. https://druglandscape.com/ci/belladonna-and-opium-suppositories. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab